Abstract. Adrenal involvement in polycystic ovarian disease was assessed by measuring dehydroepiandrosterone sulphate in 20 polycystic ovarian disease patients. The response of dehydroepiandrosterone sulphate to bromocriptine treatment was compared to that of placebo, both being given for one cycle on a doubleblind, cross over basis. The mean basal DHEA-S was above the upper limit of the normal range (6793 nmol/l) in three patients. The mean basal dehydroepiandrosterone sulphate in the polycystic ovarian disease group was significantly higher than the mean of the normal control group (P < 0.01). Dehydroepiandrosterone sulphate showed a significant drop with bromocriptine as compared to placebo (P < 0.001) and a significant correlation with prolactin both before (P < 0.001) and after treatment with bromocriptine (P < 0.001). These findings support the hypothesis of adrenal involvement in polycystic ovarian disease and prove the significant effect of bromocriptine on the adrenal which might be of therapeutic value.
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Involvement of the adrenal gland in polycystic ovarian disease (PCOD) has been recognized since Broster (1937) (Abraham et al. 1976) or stimulation with ACTH (Gibson et al. 1980) . It has been postulated that adrenal hyperfunction at the time of adrenarche may be responsible for the obesity and hirsutism in PCOD patients. Peripheral metabolism of increased adrenal androgens may result in increased oestrogen levels which provides the hormonal milieu for the development of PCOD (Goldzieher 1982) .
In that dehydroepiandrosterone sulphate (DHEA-S) is almost exclusively secreted by the adrenal gland (Vande Wiele et al. 1963) , elevation in its level may act as a marker of the adrenal involvement in PCOD. Several investigators (Buvat et al. 1982; Lobo et al. 1983) reported high DHEA-S levels in PCOD. Hyperprolactinaemia is a potential cause for such an elevation (Carmina et al. 1984) . Evidence indicates that hyperprolactin¬ aemia is not uncommon in PCOD (Wortsman & Hirschowitz 1980) Compared to placebo the decrease in DHEA-S with bromocriptine therapy was statistically signi¬ ficant (P < 0.001), as shown in Fig. 2 . Prolactin values showed a significant drop with bromocriptine treatment (from 18.6 ± 4.4 to 6.05 ± 2.07, < 0.001). Luteinizing hormone values also sig¬ nificantly dropped with bromocriptine (from 24.2 ± 9 to 15.3 ± 4.3 IU/1, < 0.001).
The decrease in DHEA-S levels occurred both in patients with elevated as well as normal basal levels and was more or less equal in both the hyperprolactinaemic (P < 0.02) and the notraoprolactinaemic subgroups (P < 0.001) (Fig. 3) (Horrocks et al. 1983 ).
Several investigators (Bassi et (Carter et al. 1977) . This is further supported by finding prolactin receptors in the adrenal gland ). Carter et al. (1977) investigated the effects of bromocriptine on prolactin and androgen levels in hyperprolactinaemic women with galactorr¬ hoea and amenorrhoea. They found that asso¬ ciated with the bromocriptine-induced fall in mean prolactin levels, there was a significant fall in DHEA-S (P < 0.0005) and DHEA (P < 0.01), while testosterone and androstenedione were un¬ changed. The insignificant drop in DHEA-S with bromocriptine observed in our study correlates with Seibel et al. (1984) findings who reported that DHEA-S levels declined in normoprolactinaemic PCOD patients given bromocriptine and in whom ovulation occurred.
It is concluded from our findings that the adrenal gland is involved in PCOD and that bro¬ mocriptine decreases the adrenal contribution to the androgenic pool in PCOD. Although the pathophysiology of adrenal involvement in PCOD cannot be settled yet, our data point to the role of prolactin and implicate a central dopamine defici¬ ency as a probable aetiologic factor. However, a direct effect of prolactin on the adrenal gland cannot be excluded. The occurrence of ovulation in PCOD patients with high basal DHEA-S and in whom DHEA-S markedly dropped with bromo¬ criptine is significant. It suggests an aetiologic role of DHEA-S in anovulation in PCOD patients and the possible therapeutic effect of bromocriptine on these patients.
